Bing

SEARCH HISTORY

Should I get rid of Mylan Labs, or hold on? A-You should love this stock. Hold and consider buying more shares of Mylan Laboratories Inc. (around $24 a share, New York Stock Exchange), because it is the class act in the generic drug industry, said Jerry ...
Chicago Tribune · 9/26/1994
Mylan NV (MYL) made public on Wednesday that it had made a proposal to acquire Perrigo Co. plc (PRGO) in a deal valued at $205 per share in cash and stock, or close to $29 billion. Under the terms of the proposal, which was delivered to Perrigo's …
The Deal Pipeline · 4/8/2015
Mylan said Wednesday it will pay $232.23 for each share of Perrigo in a mix of cash and stock, valuing Perrigo at about $34.1 billion. Perrigo says the offer isn't in its best interest and that it isn't worth as much as Mylan says. Perrigo, which is based ...
OregonLive · 4/29/2015
More from Bing News
Teva gets almost half its revenue from generic drugs. NEW YORK: Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. Mylan said that it won't think about starting talks unless ...
Times of India · 4/27/2015
A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the Mylan Inc stock. Gain access to a detailed technical analysis through moving averages buy/sell signals (simple and exponential for 5,10,20,50,100 and 200 periods) and common ...
investing.com · 6/25/2015
2009 Mylan is, of course, in full spin control mode, pumping out press releases saying that they're not to blame, and so on, as they've watched their stock prices tumble more than 10% since the news came out on Sunday. What Should Thyroid Patients Do?
thyroid.about.com · 7/28/2009
Shares of Mylan traded below the offer price of $82 in cash and stock, evidence of investor skepticism that Teva can win over the company, which has set up a defense that includes a poison pill. Analysts agreed that Teva would need to sweeten its bid to ...
Finance Yahoo · ByTova Cohen ,By Tova Cohen andCaroline Humer · 4/21/2015
Teva hired Barclays and boutique Greenhill as advisers. The announcement Tuesday sent Mylan’s stock up another 7.74%. Goldman’s asset management and wealth divisions now hold a combined position worth $1.57 billion. But the introduction of Teva …
thetally.efinancialnews.com · 4/22/2015
Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among …
YCharts · 12/31/2014
Perrigo shares on the New York Stock Exchange initially jumped well above the Mylan offer price to as high as US$215.72, but slipped back to US$197.95. Mylan shares jumped more than 15 per cent to US$68.72 on Nasdaq.
Financial Post · 4/8/2015

Mylan

Company
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 22,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase